Ignite Creation Date:
2025-12-25 @ 1:06 AM
Ignite Modification Date:
2025-12-25 @ 11:18 PM
Study NCT ID:
NCT05554393
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2022-09-22
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015470', 'term': 'Leukemia, Myeloid, Acute'}], 'ancestors': [{'id': 'D007951', 'term': 'Leukemia, Myeloid'}, {'id': 'D007938', 'term': 'Leukemia'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D001374', 'term': 'Azacitidine'}, {'id': 'D013048', 'term': 'Specimen Handling'}, {'id': 'D003561', 'term': 'Cytarabine'}, {'id': 'D003630', 'term': 'Daunorubicin'}, {'id': 'C579720', 'term': 'venetoclax'}], 'ancestors': [{'id': 'D001372', 'term': 'Aza Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}, {'id': 'D012263', 'term': 'Ribonucleosides'}, {'id': 'D019411', 'term': 'Clinical Laboratory Techniques'}, {'id': 'D019937', 'term': 'Diagnostic Techniques and Procedures'}, {'id': 'D003933', 'term': 'Diagnosis'}, {'id': 'D008919', 'term': 'Investigative Techniques'}, {'id': 'D001087', 'term': 'Arabinonucleosides'}, {'id': 'D018943', 'term': 'Anthracyclines'}, {'id': 'D009279', 'term': 'Naphthacenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D000617', 'term': 'Aminoglycosides'}, {'id': 'D006027', 'term': 'Glycosides'}, {'id': 'D002241', 'term': 'Carbohydrates'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 153}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-09-13', 'type': 'ACTUAL'}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2027-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-23', 'studyFirstSubmitDate': '2022-09-22', 'studyFirstSubmitQcDate': '2022-09-22', 'lastUpdatePostDateStruct': {'date': '2025-12-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-09-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Comparative analysis by molecular characteristics', 'timeFrame': 'Up to 10 years'}], 'primaryOutcomes': [{'measure': 'Measurable residual disease (MRD) undetectable complete remission (CR)', 'timeFrame': 'Up to 2 cycles (56 days)', 'description': 'Will assess after one induction cycle with or without the addition of venetoclax or two cycles of venetoclax and azacitidine. MRD by flow cytometry will be considered undetectable if ≤ 10\\^-3. The MRD negative CR will be assessed using European LeukemiaNet (ELN) 2017 criteria \\[Döhner 2017\\]. The analysis population for the primary outcome will be all randomized patients with the intent to treat (ITT) population. The MRD undetectable CR rate will be the number of patients with MRD undetectable CR divided by the total number of patients. The differences of MRD undetectable CR rates between the experimental groups and the control group will be estimated and the corresponding one-sided 80% confidence limit will be calculated using Normal distribution approximation. MRD non-evaluable patients will be considered as MRD positive.'}], 'secondaryOutcomes': [{'measure': 'Frequency and severity of toxicities with each of the regimens', 'timeFrame': 'Up to 10 years', 'description': "All patients who have received at least one dose of study treatment will be included in the safety analysis. Adverse events will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The incidence of adverse events will be summarized by type severity and relationship to the study drugs. A Fisher's exact test will be used to compare toxicities between the two arms, if needed."}, {'measure': 'Complete remission (CR) rates', 'timeFrame': 'Up to 2 cycles (56 days)', 'description': 'Will be assessed per 2017 ELN guidelines and will be tabulated. Exact 95% confidence intervals will be calculated.'}, {'measure': 'Complete remission with incomplete count recovery (CRi)', 'timeFrame': 'Up to 2 cycles (56 days)', 'description': 'Will be assessed with and without MRD. Will be assessed per 2017 ELN guidelines and will be tabulated. Exact 95% confidence intervals will be calculated.'}, {'measure': 'Event-free survival (EFS)', 'timeFrame': 'From the date of randomization to the first: date of primary refractory disease; date of progressive disease; date off protocol therapy without CR or CRi; date of relapse from CR or CRi, or death from any cause, assessed up to 10 years', 'description': 'Patients not known to have any of these events are censored on the date of last contact. Will be described by the Kaplan-Meier estimate, and log-rank tests will be used to test the difference between each experimental arms to the control arms.'}, {'measure': 'Relapse-free survival (RFS)', 'timeFrame': 'From the time of CR or CRi, until the relapse from CR or CRi, or death from any cause, assessed up to 10 years', 'description': 'Will be calculated for participants who have achieved a CR or CRi. For patients who have not relapsed or died, will be censored on the date of the last disease assessment. Will be described by the Kaplan-Meier estimate, and log-rank tests will be used to test the difference between each experimental arms to the control arms.'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'From randomization to the time of death from any cause, assessed up to 10 years', 'description': 'For patients who did not die, overall survival time will be censored at the time of last known alive (LKA) date. Will be described by the Kaplan-Meier estimate, and log-rank tests will be used to test the difference between each experimental arms to the control arms.'}, {'measure': 'Responses to therapy received relative to genomic findings', 'timeFrame': 'Up to 10 years', 'description': 'Will evaluate to gain insights toward more precise patient selection for optimal outcomes.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Acute Myeloid Leukemia']}, 'descriptionModule': {'briefSummary': 'This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid (DNA) replication and repair and can slow or stop the growth of cancer cells. Daunorubicin is a drug that blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Azacitidine is a drug that interacts with DNA to activate tumor-suppressing genes, resulting in an anti-tumor effect. Adding venetoclax to cytarabine and daunorubicin, and adding venetoclax to azacitidine, may work better than the usual treatment of cytarabine with daunorubicin alone. To decide if they are better, the study doctors are looking to see if venetoclax increases the rate of elimination of AML in participants by 20% or more compared to the usual approach.', 'detailedDescription': 'PRIMARY OBJECTIVE:\n\nI. To compare the rates of undetectable measurable residual disease (MRD) in patients who achieve a complete remission (CR) after induction therapy with 7 +3 (cytarabine + daunorubicin hydrochloride \\[daunorubicin\\]) versus (vs.) azacitidine + venetoclax vs. 7+3 + venetoclax.\n\nSECONDARY OBJECTIVES:\n\nI. To estimate the frequency and severity of toxicities with each of the regimens.\n\nII. To estimate complete remission (CR) rates (with and without MRD), complete remission with incomplete count recovery (CRi) (with and without MRD) rates, event-free survival (EFS), relapse-free survival (RFS), and overall survival (OS) with each of the regimens.\n\nTERTIARY OBJECTIVES:\n\nI. To evaluate response to therapy received according to genomic findings. II. To evaluate MRD kinetics by following patients with detectable MRD through Tier 2 and beyond.\n\nIII. To evaluate longer term outcomes by treatment arm, genomics, MRD outcome, and other features as patients receive additional myeloMATCH therapies to generate testable hypotheses for more precise patient selection for these therapies.\n\nOUTLINE: Patients are randomized to 1 of 3 arms.\n\nARM I: Patients receive daunorubicin intravenously (IV) on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax orally (PO) once per day (QD) on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment, patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.\n\nARM II: Patients receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.\n\nARM III: Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment, patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.\n\nAfter completion of study treatment, patients are followed up at 4 weeks, every 3 months for 1 year every 6 months for the second year and yearly thereafter.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '59 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patient must have enrolled onto MYELOMATCH and must have been given a treatment assignment to MyeloMATCH to MM1YA-CTG01 based on the presence of an actionable mutation as defined in MYELOMATCH\n* Participants must have been registered to master screening and re-assessment protocol (myeloMATCH MSRP) prior to consenting to this study. Participants must have been assigned to this clinical trial, via MATCHBox, prior to registration to this study. Participants must have agreed to have specimens submitted for translational medicine (MRD) and must be offered the opportunity to submit biosamples for banking for future research as per the myeloMATCH MSRP\n\n * Note: Pre-enrollment/diagnosis labs must have already been performed under the MSRP\n* Previously untreated, de novo acute myeloid leukemia (AML) defined by \\> 20% myeloblasts in the peripheral blood or bone marrow (refer to the 2016 updated World Health Organization \\[WHO\\] classification of myeloid neoplasms and acute leukemia) excluding all the following categories of AML:\n\n * Favorable cytogenetics: (t(8;21)q22;q22.1); RUNX1-RUNX1T1, inversion 16(p13.1;q22), t(16;16)(p13.1;q22); CBFB-MYH11\n * CEBPA biallelic mutations\n * NPM1 mutation\n * AML with PML-RARalpha\n * AML with any adverse cytogenetics, TP53 mutation, RUNX1 mutation, ASXL1, 11q23/KMT2 rearrangements\n * AML with FLT3-ITD or FLT3-TKD mutations\n * Therapy related AML, or AML following a diagnosis of myelodysplasia or myeloproliferative neoplasm Participants with central nervous system (CNS) disease are eligible for this trial and will be treated according to institutional guidelines with intrathecal chemotherapy for this aspect of their disease\n* Age 18-59 years at time of induction therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\< 3\n* Total bilirubin =\\< 2 x institutional upper limit of normal (ULN) (must be done within 7 days of enrollment)\n* Aspartate aminotransferase (AST) (serum glutamate pyruvate transaminase \\[SGPT\\]) +/or alanine aminotransferase (ALT) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]) =\\< 3 × institutional ULN (must be done within 7 days of enrollment)\n* Cardiac ejection fraction \\>= 50% (echocardiography or multigated acquisition scan \\[MUGA\\]) (must be done within 7 days of enrollment)\n* Calculated creatinine clearance \\>= 30 mL/min/ 1.73m\\^2; Clearance to be calculated using Cockcroft formula (must be done within 7 days of enrollment)\n* White blood cells (WBC) must be \\< 25 x 10\\^9/L. Hydroxyurea and leukapheresis are permitted to control the WBC prior to enrollment and initiation of protocol-defined therapy but must be stopped at least 24 hours prior to the initiation of protocol therapy\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better\n* Women/men of childbearing potential must have agreed to use a highly effective contraceptive method while on treatment and for 6 months after stopping study drug. A woman is considered to be of "childbearing potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures.\n\nWomen of childbearing potential will have a pregnancy test to determine eligibility as part of the pre-study evaluation; this may include an ultrasound to rule-out pregnancy if a false-positive is suspected. Patient will be considered eligible if an ultrasound is negative for pregnancy\n\n* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate\n* Patients must be accessible for treatment, response assessment and follow up. Patients enrolled on this trial must be treated and followed at the participating centre. Investigators must assure themselves the patients enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.\n\nPatients must agree to return to their primary care facility for any adverse events which may occur through the course of the trial\n\n* In accordance with Canadian Cancer Trials Group (CCTG) policy, protocol treatment is to begin within 7 working days of patient enrollment\n* Participants receiving strong or moderate CYP3A inhibitors must agree to discontinue use at least 48 hours prior to start of study treatment if assigned to arm 1 or 2\n* Patients with known human immunodeficiency virus (HIV) infection who are on effective anti-retroviral therapy and have undetectable viral load within 6 months of enrollment are eligible for this trial\n* Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load within 28 days of enrollment. Patients need to be on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection who have been treated and cured are eligible. Patients who with active HCV infection who are currently being treated must have an undetectable HCV viral load within 28 days of enrollment to be eligible\n\nExclusion Criteria:\n\n* Prior therapy for AML except for hydroxyurea and leukapheresis to control blood counts. The use of all-trans retinoic acid (ATRA) is permitted until a diagnosis of acute promyelocytic leukemia, if suspected, is ruled out\n* Patients who are receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to cytarabine, daunorubicin, azacitidine, venetoclax\n* Pregnant women are excluded from this study because venetoclax, cytarabine and azacitidine have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, cytarabine and azacitidine breastfeeding should be discontinued if the mother is treated with venetoclax, cytarabine and azacitidine. These potential risks may also apply to other agents used in this study\n* Patients with isolated myeloid sarcoma are not eligible\n* Any other serious intercurrent illness, life threatening condition, organ system dysfunction, or medical condition judged by the local investigator to compromise the subject\'s safety (for example):\n\n * Active, uncontrolled bacterial, fungal, or viral infection'}, 'identificationModule': {'nctId': 'NCT05554393', 'briefTitle': 'Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)', 'organization': {'class': 'NIH', 'fullName': 'National Cancer Institute (NCI)'}, 'officialTitle': 'A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial', 'orgStudyIdInfo': {'id': 'NCI-2022-07534'}, 'secondaryIdInfos': [{'id': 'NCI-2022-07534', 'type': 'REGISTRY', 'domain': 'CTRP (Clinical Trial Reporting Program)'}, {'id': 'MM1YA-CTG01', 'type': 'OTHER', 'domain': 'Canadian Cancer Trials Group'}, {'id': 'MM1YA-CTG01', 'type': 'OTHER', 'domain': 'CTEP'}, {'id': 'U10CA180863', 'link': 'https://reporter.nih.gov/quickSearch/U10CA180863', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'ARM I (daunorubicin, cytarabine, venetoclax)', 'description': 'Patients receive daunorubicin IV on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax PO QD on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment, patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.', 'interventionNames': ['Procedure: Biospecimen Collection', 'Procedure: Bone Marrow Aspiration', 'Drug: Cytarabine', 'Drug: Daunorubicin Hydrochloride', 'Drug: Venetoclax']}, {'type': 'EXPERIMENTAL', 'label': 'ARM II (azacitidine, venetoclax)', 'description': 'Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.', 'interventionNames': ['Drug: Azacitidine', 'Procedure: Biospecimen Collection', 'Procedure: Bone Marrow Aspiration', 'Drug: Venetoclax']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'ARM III (daunorubicin, cytarabine)', 'description': 'Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment, patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.', 'interventionNames': ['Procedure: Biospecimen Collection', 'Procedure: Bone Marrow Aspiration', 'Drug: Cytarabine', 'Drug: Daunorubicin Hydrochloride']}], 'interventions': [{'name': 'Azacitidine', 'type': 'DRUG', 'otherNames': ['5 AZC', '5-AC', '5-Azacitidine', '5-Azacytidine', '5-AZC', 'Azacytidine', 'Azacytidine, 5-', 'Ladakamycin', 'Mylosar', 'U-18496', 'Vidaza'], 'description': 'Given IV or SC', 'armGroupLabels': ['ARM II (azacitidine, venetoclax)']}, {'name': 'Biospecimen Collection', 'type': 'PROCEDURE', 'otherNames': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'description': 'Undergo collection of blood samples', 'armGroupLabels': ['ARM I (daunorubicin, cytarabine, venetoclax)', 'ARM II (azacitidine, venetoclax)', 'ARM III (daunorubicin, cytarabine)']}, {'name': 'Bone Marrow Aspiration', 'type': 'PROCEDURE', 'description': 'Undergo bone marrow aspiration', 'armGroupLabels': ['ARM I (daunorubicin, cytarabine, venetoclax)', 'ARM II (azacitidine, venetoclax)', 'ARM III (daunorubicin, cytarabine)']}, {'name': 'Cytarabine', 'type': 'DRUG', 'otherNames': ['.beta.-Cytosine arabinoside', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', '1-.beta.-D-Arabinofuranosylcytosine', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', '1-Beta-D-arabinofuranosylcytosine', '1.beta.-D-Arabinofuranosylcytosine', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', 'Alexan', 'Ara-C', 'ARA-cell', 'Arabine', 'Arabinofuranosylcytosine', 'Arabinosylcytosine', 'Aracytidine', 'Aracytin', 'Aracytine', 'Beta-Cytosine Arabinoside', 'CHX-3311', 'Cytarabinum', 'Cytarbel', 'Cytosar', 'Cytosine Arabinoside', 'Cytosine-.beta.-arabinoside', 'Cytosine-beta-arabinoside', 'Erpalfa', 'Starasid', 'Tarabine PFS', 'U 19920', 'U-19920', 'Udicil', 'WR-28453'], 'description': 'Given IV', 'armGroupLabels': ['ARM I (daunorubicin, cytarabine, venetoclax)', 'ARM III (daunorubicin, cytarabine)']}, {'name': 'Daunorubicin Hydrochloride', 'type': 'DRUG', 'otherNames': ['Cerubidin', 'Cerubidine', 'Cloridrato de Daunorubicina', 'Daunoblastin', 'Daunoblastina', 'Daunoblastine', 'Daunomycin Hydrochloride', 'Daunomycin, hydrochloride', 'Daunorubicin.HCl', 'Daunorubicini Hydrochloridum', 'FI-6339', 'Ondena', 'RP-13057', 'Rubidomycin Hydrochloride', 'Rubilem'], 'description': 'Given IV', 'armGroupLabels': ['ARM I (daunorubicin, cytarabine, venetoclax)', 'ARM III (daunorubicin, cytarabine)']}, {'name': 'Venetoclax', 'type': 'DRUG', 'otherNames': ['ABT 199', 'ABT-0199', 'ABT-199', 'ABT199', 'GDC 0199', 'GDC-0199', 'GDC0199', 'RG7601', 'Venclexta', 'Venclyxto'], 'description': 'Given PO', 'armGroupLabels': ['ARM I (daunorubicin, cytarabine, venetoclax)', 'ARM II (azacitidine, venetoclax)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35233', 'city': 'Birmingham', 'state': 'Alabama', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'charlesbaldwin@uabmc.edu', 'phone': '205-895-1816'}, {'name': 'Razan Mohty', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Alabama at Birmingham Cancer Center', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '85719', 'city': 'Tucson', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'UACC-IIT@uacc.arizona.edu'}, {'name': 'Sharad Khurana', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Banner University Medical Center - Tucson', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '85719', 'city': 'Tucson', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'UACC-IIT@uacc.arizona.edu'}, {'name': 'Sharad Khurana', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Arizona Cancer Center-North Campus', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '72205', 'city': 'Little Rock', 'state': 'Arkansas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '501-686-8274'}, {'name': 'Ankur Varma', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Arkansas for Medical Sciences', 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'zip': '94704', 'city': 'Berkeley', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'clinicalresearch@sutterhealth.org'}, {'name': 'Ari D. Baron', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Alta Bates Summit Medical Center-Herrick Campus', 'geoPoint': {'lat': 37.87159, 'lon': -122.27275}}, {'zip': '90048', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '310-423-8965'}, {'name': 'Noah M. Merin', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Cedars Sinai Medical Center', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '94143', 'city': 'San Francisco', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '877-827-3222'}, {'name': 'Timothy Ferng', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UCSF Medical Center-Parnassus', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '31701', 'city': 'Albany', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'ga_cares@augusta.edu', 'phone': '229-312-0405'}, {'name': 'Vamsi Kota', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Phoebe Putney Memorial Hospital', 'geoPoint': {'lat': 31.57851, 'lon': -84.15574}}, {'zip': '83706', 'city': 'Boise', 'state': 'Idaho', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'stephanie.couch@stjoeshealth.org', 'phone': '734-712-3671'}, {'name': 'Tareq Al baghdadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Saint Alphonsus Cancer Care Center-Boise', 'geoPoint': {'lat': 43.6135, 'lon': -116.20345}}, {'zip': '83712', 'city': 'Boise', 'state': 'Idaho', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'eslinget@slhs.org', 'phone': '208-381-2774'}, {'name': 'Charles W. Drescher', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Saint Luke's Cancer Institute - Boise", 'geoPoint': {'lat': 43.6135, 'lon': -116.20345}}, {'zip': '83605', 'city': 'Caldwell', 'state': 'Idaho', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'stephanie.couch@stjoeshealth.org', 'phone': '734-712-3671'}, {'name': 'Tareq Al baghdadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Saint Alphonsus Cancer Care Center-Caldwell', 'geoPoint': {'lat': 43.66294, 'lon': -116.68736}}, {'zip': '83814', 'city': "Coeur d'Alene", 'state': 'Idaho', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mccinfo@mtcancer.org', 'phone': '406-969-6060'}, {'name': 'John M. Schallenkamp', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Kootenai Health - Coeur d'Alene", 'geoPoint': {'lat': 47.67768, 'lon': -116.78047}}, {'zip': '83619', 'city': 'Fruitland', 'state': 'Idaho', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'eslinget@slhs.org', 'phone': '208-381-2774'}, {'name': 'Charles W. Drescher', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Saint Luke's Cancer Institute - Fruitland", 'geoPoint': {'lat': 44.00766, 'lon': -116.91655}}, {'zip': '83642', 'city': 'Meridian', 'state': 'Idaho', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'eslinget@slhs.org', 'phone': '208-381-2774'}, {'name': 'Charles W. Drescher', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Saint Luke's Cancer Institute - Meridian", 'geoPoint': {'lat': 43.61211, 'lon': -116.39151}}, {'zip': '83687', 'city': 'Nampa', 'state': 'Idaho', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mccinfo@mtcancer.org', 'phone': '406-969-6060'}, {'name': 'Tareq Al baghdadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Saint Alphonsus Cancer Care Center-Nampa', 'geoPoint': {'lat': 43.54072, 'lon': -116.56346}}, {'zip': '83687', 'city': 'Nampa', 'state': 'Idaho', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'eslinget@slhs.org', 'phone': '208-381-2774'}, {'name': 'Charles W. Drescher', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Saint Luke's Cancer Institute - Nampa", 'geoPoint': {'lat': 43.54072, 'lon': -116.56346}}, {'zip': '83854', 'city': 'Post Falls', 'state': 'Idaho', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mccinfo@mtcancer.org', 'phone': '406-969-6060'}, {'name': 'John M. Schallenkamp', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Kootenai Clinic Cancer Services - Post Falls', 'geoPoint': {'lat': 47.71796, 'lon': -116.95159}}, {'zip': '83864', 'city': 'Sandpoint', 'state': 'Idaho', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mccinfo@mtcancer.org', 'phone': '406-969-6060'}, {'name': 'John M. Schallenkamp', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Kootenai Clinic Cancer Services - Sandpoint', 'geoPoint': {'lat': 48.27659, 'lon': -116.55325}}, {'zip': '62801', 'city': 'Centralia', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'morganthaler.jodi@mhsil.com', 'phone': '217-876-4762'}, {'name': 'Bryan A. Faller', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centralia Oncology Clinic', 'geoPoint': {'lat': 38.52505, 'lon': -89.1334}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'cancer@northwestern.edu', 'phone': '312-695-1301'}, {'name': 'Shira N. Dinner', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Northwestern University', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60637', 'city': 'Chicago', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'cancerclinicaltrials@bsd.uchicago.edu', 'phone': '773-702-8222'}, {'name': 'Olatoyosi M. Odenike', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Chicago Comprehensive Cancer Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '62526', 'city': 'Decatur', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'morganthaler.jodi@mhsil.com', 'phone': '217-876-4762'}, {'name': 'Bryan A. Faller', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Cancer Care Specialists of Illinois - Decatur', 'geoPoint': {'lat': 39.84031, 'lon': -88.9548}}, {'zip': '62526', 'city': 'Decatur', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'morganthaler.jodi@mhsil.com', 'phone': '217-876-4762'}, {'name': 'Bryan A. Faller', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Decatur Memorial Hospital', 'geoPoint': {'lat': 39.84031, 'lon': -88.9548}}, {'zip': '62401', 'city': 'Effingham', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'morganthaler.jodi@mhsil.com', 'phone': '217-876-4762'}, {'name': 'Bryan A. Faller', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Crossroads Cancer Center', 'geoPoint': {'lat': 39.12004, 'lon': -88.54338}}, {'zip': '60201', 'city': 'Evanston', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '847-570-2109'}, {'name': 'Amy Y. Wang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'NorthShore University HealthSystem-Evanston Hospital', 'geoPoint': {'lat': 42.04114, 'lon': -87.69006}}, {'zip': '60026', 'city': 'Glenview', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '847-570-2109'}, {'name': 'Amy Y. Wang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'NorthShore University HealthSystem-Glenbrook Hospital', 'geoPoint': {'lat': 42.06975, 'lon': -87.78784}}, {'zip': '60035', 'city': 'Highland Park', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '847-570-2109'}, {'name': 'Amy Y. Wang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'NorthShore University HealthSystem-Highland Park Hospital', 'geoPoint': {'lat': 42.18169, 'lon': -87.80034}}, {'zip': '60153', 'city': 'Maywood', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '708-226-4357'}, {'name': 'Stephanie B. Tsai', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Loyola University Medical Center', 'geoPoint': {'lat': 41.8792, 'lon': -87.84312}}, {'zip': '60451', 'city': 'New Lenox', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'cancerclinicaltrials@bsd.uchicago.edu', 'phone': '773-702-8222'}, {'name': 'Olatoyosi M. Odenike', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UC Comprehensive Cancer Center at Silver Cross', 'geoPoint': {'lat': 41.51198, 'lon': -87.96561}}, {'zip': '62269', 'city': "O'Fallon", 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'morganthaler.jodi@mhsil.com', 'phone': '217-876-4762'}, {'name': 'Bryan A. Faller', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Cancer Care Center of O'Fallon", 'geoPoint': {'lat': 38.59227, 'lon': -89.91121}}, {'zip': '60462', 'city': 'Orland Park', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'cancerclinicaltrials@bsd.uchicago.edu', 'phone': '773-702-8222'}, {'name': 'Olatoyosi M. Odenike', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Chicago Medicine-Orland Park', 'geoPoint': {'lat': 41.63031, 'lon': -87.85394}}, {'zip': '62702', 'city': 'Springfield', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '217-545-7929'}, {'name': 'Bryan A. Faller', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Southern Illinois University School of Medicine', 'geoPoint': {'lat': 39.80172, 'lon': -89.64371}}, {'zip': '62702', 'city': 'Springfield', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '800-444-7541'}, {'name': 'Bryan A. Faller', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Springfield Clinic', 'geoPoint': {'lat': 39.80172, 'lon': -89.64371}}, {'zip': '62781', 'city': 'Springfield', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'pallante.beth@mhsil.com', 'phone': '217-528-7541'}, {'name': 'Bryan A. Faller', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Springfield Memorial Hospital', 'geoPoint': {'lat': 39.80172, 'lon': -89.64371}}, {'zip': '46307', 'city': 'Crown Point', 'state': 'Indiana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'cancerclinicaltrials@bsd.uchicago.edu', 'phone': '855-702-8222'}, {'name': 'Olatoyosi M. Odenike', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UChicago Medicine Northwest Indiana', 'geoPoint': {'lat': 41.41698, 'lon': -87.36531}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '800-237-1225'}, {'name': 'Prajwal Dhakal', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Iowa/Holden Comprehensive Cancer Center', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '66205', 'city': 'Fairway', 'state': 'Kansas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'KUCC_Navigation@kumc.edu', 'phone': '913-588-3671'}, {'name': 'Heather J. Male', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Kansas Clinical Research Center', 'geoPoint': {'lat': 39.02223, 'lon': -94.6319}}, {'zip': '66160', 'city': 'Kansas City', 'state': 'Kansas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'KUCC_Navigation@kumc.edu', 'phone': '913-588-3671'}, {'name': 'Heather J. Male', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Kansas Cancer Center', 'geoPoint': {'lat': 39.11417, 'lon': -94.62746}}, {'zip': '66211', 'city': 'Overland Park', 'state': 'Kansas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'KUCC_Navigation@kumc.edu', 'phone': '913-588-3671'}, {'name': 'Heather J. Male', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Kansas Hospital-Indian Creek Campus', 'geoPoint': {'lat': 38.98223, 'lon': -94.67079}}, {'zip': '66205', 'city': 'Westwood', 'state': 'Kansas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'KUCC_Navigation@kumc.edu', 'phone': '913-588-3671'}, {'name': 'Heather J. Male', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Kansas Hospital-Westwood Cancer Center', 'geoPoint': {'lat': 39.04056, 'lon': -94.6169}}, {'zip': '40536', 'city': 'Lexington', 'state': 'Kentucky', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '859-257-3379'}, {'name': 'Ayman Qasrawi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Kentucky/Markey Cancer Center', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'zip': '40202', 'city': 'Louisville', 'state': 'Kentucky', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '502-562-3429'}, {'name': 'Mohamed M. Hegazi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'The James Graham Brown Cancer Center at University of Louisville', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '40245', 'city': 'Louisville', 'state': 'Kentucky', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'ctoinfo@louisville.edu', 'phone': '502-852-2755'}, {'name': 'Mohamed M. Hegazi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UofL Health Medical Center Northeast', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '70805', 'city': 'Baton Rouge', 'state': 'Louisiana', 'status': 'SUSPENDED', 'country': 'United States', 'facility': 'LSU Health Baton Rouge-North Clinic', 'geoPoint': {'lat': 30.44332, 'lon': -91.18747}}, {'zip': '70808', 'city': 'Baton Rouge', 'state': 'Louisiana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'research@ololrmc.com', 'phone': '225-765-7659'}, {'name': 'Harry G. Sequeira Gross', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Our Lady of the Lake Physician Group', 'geoPoint': {'lat': 30.44332, 'lon': -91.18747}}, {'zip': '70808', 'city': 'Baton Rouge', 'state': 'Louisiana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '225-765-7659'}, {'name': 'Harry G. Sequeira Gross', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Our Lady of The Lake', 'geoPoint': {'lat': 30.44332, 'lon': -91.18747}}, {'zip': '04102', 'city': 'Portland', 'state': 'Maine', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'clinicalresearch@mainehealth.org', 'phone': '207-396-8670'}, {'name': 'Pamela Egan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'MaineHealth Maine Medical Center - Portland', 'geoPoint': {'lat': 43.65737, 'lon': -70.2589}}, {'zip': '04106', 'city': 'South Portland', 'state': 'Maine', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'clinicalresearch@mainehealth.org', 'phone': '207-396-8670'}, {'name': 'Pamela Egan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'MaineHealth Cancer Care and IV Therapy - South Portland', 'geoPoint': {'lat': 43.64147, 'lon': -70.24088}}, {'zip': '02111', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'ContactUsCancerCenter@TuftsMedicalCenter.org', 'phone': '617-636-5000'}, {'name': 'Andreas K. Klein', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Tufts Medical Center', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '02215', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '877-442-3324'}, {'name': 'Eric S. Winer', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Dana-Farber Cancer Institute', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '01805', 'city': 'Burlington', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'lhmc-cancer-clinical-trials@lahey.org', 'phone': '781-744-3421'}, {'name': 'Samer Ibrahim', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Lahey Hospital and Medical Center', 'geoPoint': {'lat': 42.50482, 'lon': -71.19561}}, {'zip': '01960', 'city': 'Peabody', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'lhmc-cancer-clinical-trials@lahey.org', 'phone': '781-744-3421'}, {'name': 'Samer Ibrahim', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Lahey Medical Center-Peabody', 'geoPoint': {'lat': 42.52787, 'lon': -70.92866}}, {'zip': '48114', 'city': 'Brighton', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'MCRCwebsitecontactform@stjoeshealth.org', 'phone': '734-712-7251'}, {'name': 'Tareq Al baghdadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Trinity Health IHA Medical Group Hematology Oncology - Brighton', 'geoPoint': {'lat': 42.52948, 'lon': -83.78022}}, {'zip': '48188', 'city': 'Canton', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'MCRCwebsitecontactform@stjoeshealth.org', 'phone': '734-712-7251'}, {'name': 'Tareq Al baghdadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Trinity Health IHA Medical Group Hematology Oncology - Canton', 'geoPoint': {'lat': 42.30865, 'lon': -83.48216}}, {'zip': '48118', 'city': 'Chelsea', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'MCRCwebsitecontactform@stjoeshealth.org', 'phone': '734-712-7251'}, {'name': 'Tareq Al baghdadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital', 'geoPoint': {'lat': 42.31807, 'lon': -84.02181}}, {'zip': '48038', 'city': 'Clinton Township', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CTOResearch@hfhs.org', 'phone': '313-916-3721'}, {'name': 'Christopher A. Willner', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Henry Ford Macomb Hospital-Clinton Township', 'geoPoint': {'lat': 42.58698, 'lon': -82.91992}}, {'zip': '48202', 'city': 'Detroit', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CTOResearch@hfhs.org', 'phone': '313-916-3721'}, {'name': 'Christopher A. Willner', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Henry Ford Hospital', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '48503', 'city': 'Flint', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'wstrong@ghci.org', 'phone': '810-762-8038'}, {'name': 'Tareq Al baghdadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Cancer Hematology Centers - Flint', 'geoPoint': {'lat': 43.01253, 'lon': -83.68746}}, {'zip': '48503', 'city': 'Flint', 'state': 'Michigan', 'status': 'SUSPENDED', 'country': 'United States', 'facility': 'Genesee Hematology Oncology PC', 'geoPoint': {'lat': 43.01253, 'lon': -83.68746}}, {'zip': '48503', 'city': 'Flint', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'wstrong@ghci.org', 'phone': '810-762-8038'}, {'name': 'Tareq Al baghdadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Genesys Hurley Cancer Institute', 'geoPoint': {'lat': 43.01253, 'lon': -83.68746}}, {'zip': '48503', 'city': 'Flint', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'wstrong@ghci.org', 'phone': '810-762-8038'}, {'name': 'Tareq Al baghdadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hurley Medical Center', 'geoPoint': {'lat': 43.01253, 'lon': -83.68746}}, {'zip': '49201', 'city': 'Jackson', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CTOResearch@hfhs.org', 'phone': '313-916-3721'}, {'name': 'Christopher A. Willner', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Allegiance Health', 'geoPoint': {'lat': 42.24587, 'lon': -84.40135}}, {'zip': '48154', 'city': 'Livonia', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'MCRCwebsitecontactform@stjoeshealth.org', 'phone': '734-712-7251'}, {'name': 'Tareq Al baghdadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Trinity Health Saint Mary Mercy Livonia Hospital', 'geoPoint': {'lat': 42.36837, 'lon': -83.35271}}, {'zip': '48377', 'city': 'Novi', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CTOResearch@hfhs.org', 'phone': '313-916-3721'}, {'name': 'Christopher A. Willner', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Henry Ford Medical Center-Columbus', 'geoPoint': {'lat': 42.48059, 'lon': -83.47549}}, {'zip': '48322', 'city': 'West Bloomfield', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CTOResearch@hfhs.org', 'phone': '313-916-3721'}, {'name': 'Christopher A. Willner', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Henry Ford West Bloomfield Hospital', 'geoPoint': {'lat': 42.56891, 'lon': -83.38356}}, {'zip': '48197', 'city': 'Ypsilanti', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'MCRCwebsitecontactform@stjoeshealth.org', 'phone': '734-712-7251'}, {'name': 'Tareq Al baghdadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus', 'geoPoint': {'lat': 42.24115, 'lon': -83.61299}}, {'zip': '55433', 'city': 'Coon Rapids', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mmcorc@healthpartners.com', 'phone': '952-993-1517'}, {'name': 'David M. King', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Mercy Hospital', 'geoPoint': {'lat': 45.11997, 'lon': -93.28773}}, {'zip': '56636', 'city': 'Deer River', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CancerTrials@EssentiaHealth.org', 'phone': '218-786-3308'}, {'name': 'Bret E. Friday', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Essentia Health - Deer River Clinic', 'geoPoint': {'lat': 47.333, 'lon': -93.79272}}, {'zip': '55805', 'city': 'Duluth', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CancerTrials@EssentiaHealth.org', 'phone': '218-786-3308'}, {'name': 'Bret E. Friday', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Essentia Health Cancer Center', 'geoPoint': {'lat': 46.78327, 'lon': -92.10658}}, {'zip': '55435', 'city': 'Edina', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mmcorc@healthpartners.com', 'phone': '952-993-1517'}, {'name': 'David M. King', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Fairview Southdale Hospital', 'geoPoint': {'lat': 44.88969, 'lon': -93.34995}}, {'zip': '55746', 'city': 'Hibbing', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '218-786-3308'}, {'name': 'Bret E. Friday', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Essentia Health Hibbing Clinic', 'geoPoint': {'lat': 47.42715, 'lon': -92.93769}}, {'zip': '55407', 'city': 'Minneapolis', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mmcorc@healthpartners.com', 'phone': '952-993-1517'}, {'name': 'David M. King', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Abbott-Northwestern Hospital', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'zip': '55416', 'city': 'Saint Louis Park', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mmcorc@healthpartners.com', 'phone': '952-993-1517'}, {'name': 'David M. King', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Park Nicollet Clinic - Saint Louis Park', 'geoPoint': {'lat': 44.9483, 'lon': -93.34801}}, {'zip': '55101', 'city': 'Saint Paul', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mmcorc@healthpartners.com', 'phone': '952-993-1517'}, {'name': 'David M. King', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Regions Hospital', 'geoPoint': {'lat': 44.94441, 'lon': -93.09327}}, {'zip': '55102', 'city': 'Saint Paul', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mmcorc@healthpartners.com', 'phone': '952-993-1517'}, {'name': 'David M. King', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'United Hospital', 'geoPoint': {'lat': 44.94441, 'lon': -93.09327}}, {'zip': '55072', 'city': 'Sandstone', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CancerTrials@EssentiaHealth.org', 'phone': '218-786-3308'}, {'name': 'Bret E. Friday', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Essentia Health Sandstone', 'geoPoint': {'lat': 46.13106, 'lon': -92.86742}}, {'zip': '55792', 'city': 'Virginia', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CancerTrials@EssentiaHealth.org', 'phone': '218-786-3308'}, {'name': 'Bret E. Friday', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Essentia Health Virginia Clinic', 'geoPoint': {'lat': 47.52326, 'lon': -92.53657}}, {'zip': '39705', 'city': 'Columbus', 'state': 'Mississippi', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'BCCclintrials@bmhcc.org', 'phone': '901-226-1366'}, {'name': 'Salil Goorha', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Baptist Memorial Hospital and Cancer Center-Golden Triangle', 'geoPoint': {'lat': 33.49567, 'lon': -88.42726}}, {'zip': '38901', 'city': 'Grenada', 'state': 'Mississippi', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'BCCclintrials@bmhcc.org', 'phone': '901-226-1366'}, {'name': 'Salil Goorha', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Baptist Cancer Center-Grenada', 'geoPoint': {'lat': 33.769, 'lon': -89.80842}}, {'zip': '38652', 'city': 'New Albany', 'state': 'Mississippi', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'BCCclintrials@bmhcc.org', 'phone': '901-226-1366'}, {'name': 'Salil Goorha', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Baptist Memorial Hospital and Cancer Center-Union County', 'geoPoint': {'lat': 34.49427, 'lon': -89.00784}}, {'zip': '38655', 'city': 'Oxford', 'state': 'Mississippi', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'BCCclintrials@bmhcc.org', 'phone': '901-226-1366'}, {'name': 'Salil Goorha', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Baptist Memorial Hospital and Cancer Center-Oxford', 'geoPoint': {'lat': 34.3665, 'lon': -89.51925}}, {'zip': '38671', 'city': 'Southhaven', 'state': 'Mississippi', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'BCCclintrials@bmhcc.org', 'phone': '901-226-1366'}, {'name': 'Salil Goorha', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Baptist Memorial Hospital and Cancer Center-Desoto', 'geoPoint': {'lat': 34.99176, 'lon': -90.12759}}, {'zip': '63376', 'city': 'City of Saint Peters', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'info@siteman.wustl.edu', 'phone': '800-600-3606'}, {'name': 'Ramzi Abboud', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Siteman Cancer Center at Saint Peters Hospital', 'geoPoint': {'lat': 38.80033, 'lon': -90.62651}}, {'zip': '63141', 'city': 'Creve Coeur', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'info@siteman.wustl.edu', 'phone': '800-600-3606'}, {'name': 'Ramzi Abboud', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Siteman Cancer Center at West County Hospital', 'geoPoint': {'lat': 38.66089, 'lon': -90.42262}}, {'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'info@siteman.wustl.edu', 'phone': '800-600-3606'}, {'name': 'Ramzi Abboud', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Washington University School of Medicine', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '63129', 'city': 'St Louis', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'info@siteman.wustl.edu', 'phone': '800-600-3606'}, {'name': 'Ramzi Abboud', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Siteman Cancer Center-South County', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '63136', 'city': 'St Louis', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'info@siteman.wustl.edu', 'phone': '800-600-3606'}, {'name': 'Ramzi Abboud', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Siteman Cancer Center at Christian Hospital', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '59711', 'city': 'Anaconda', 'state': 'Montana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mccinfo@mtcancer.org', 'phone': '406-969-6060'}, {'name': 'John M. Schallenkamp', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Community Hospital of Anaconda', 'geoPoint': {'lat': 46.12854, 'lon': -112.94226}}, {'zip': '59101', 'city': 'Billings', 'state': 'Montana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'research@billingsclinic.org', 'phone': '800-996-2663'}, {'name': 'John M. Schallenkamp', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Billings Clinic Cancer Center', 'geoPoint': {'lat': 45.78329, 'lon': -108.50069}}, {'zip': '59715', 'city': 'Bozeman', 'state': 'Montana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mccinfo@mtcancer.org', 'phone': '406-969-6060'}, {'name': 'John M. Schallenkamp', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Bozeman Health Deaconess Hospital', 'geoPoint': {'lat': 45.67965, 'lon': -111.03856}}, {'zip': '59405', 'city': 'Great Falls', 'state': 'Montana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mccinfo@mtcancer.org', 'phone': '406-969-6060'}, {'name': 'John M. Schallenkamp', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Benefis Sletten Cancer Institute', 'geoPoint': {'lat': 47.50024, 'lon': -111.30081}}, {'zip': '59901', 'city': 'Kalispell', 'state': 'Montana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mccinfo@mtcancer.org', 'phone': '406-969-6060'}, {'name': 'John M. Schallenkamp', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Logan Health Medical Center', 'geoPoint': {'lat': 48.19579, 'lon': -114.31291}}, {'zip': '59804', 'city': 'Missoula', 'state': 'Montana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mccinfo@mtcancer.org', 'phone': '406-969-6060'}, {'name': 'John M. Schallenkamp', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Community Medical Center', 'geoPoint': {'lat': 46.87215, 'lon': -113.994}}, {'zip': '68123', 'city': 'Bellevue', 'state': 'Nebraska', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'unmcrsa@unmc.edu', 'phone': '402-559-6941'}, {'name': 'Michael Haddadin', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Nebraska Medicine-Bellevue', 'geoPoint': {'lat': 41.13667, 'lon': -95.89084}}, {'zip': '68118', 'city': 'Omaha', 'state': 'Nebraska', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '402-559-5600'}, {'name': 'Michael Haddadin', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Nebraska Medicine-Village Pointe', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '68198', 'city': 'Omaha', 'state': 'Nebraska', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'unmcrsa@unmc.edu', 'phone': '402-559-6941'}, {'name': 'Michael Haddadin', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Nebraska Medical Center', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '89052', 'city': 'Henderson', 'state': 'Nevada', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'research@sncrf.org', 'phone': '702-384-0013'}, {'name': 'John A. Ellerton', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'OptumCare Cancer Care at Seven Hills', 'geoPoint': {'lat': 36.0397, 'lon': -114.98194}}, {'zip': '89102', 'city': 'Las Vegas', 'state': 'Nevada', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'research@sncrf.org', 'phone': '702-384-0013'}, {'name': 'John A. Ellerton', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'OptumCare Cancer Care at Charleston', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '89148', 'city': 'Las Vegas', 'state': 'Nevada', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'research@sncrf.org', 'phone': '702-384-0013'}, {'name': 'John A. Ellerton', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'OptumCare Cancer Care at Fort Apache', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '03756', 'city': 'Lebanon', 'state': 'New Hampshire', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'cancer.research.nurse@dartmouth.edu', 'phone': '800-639-6918'}, {'name': 'Raphael A. Lizcano', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center', 'geoPoint': {'lat': 43.64229, 'lon': -72.25176}}, {'zip': '07920', 'city': 'Basking Ridge', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '212-639-7592'}, {'name': 'Xin Wang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Memorial Sloan Kettering Basking Ridge', 'geoPoint': {'lat': 40.70621, 'lon': -74.54932}}, {'zip': '07039', 'city': 'Livingston', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'joanne.loeb@rwjbh.org', 'phone': '973-322-2934'}, {'name': 'Neil D. Palmisiano', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Saint Barnabas Medical Center', 'geoPoint': {'lat': 40.79593, 'lon': -74.31487}}, {'zip': '07740', 'city': 'Long Branch', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mary.danish@rwjbh.org', 'phone': '732-923-6564'}, {'name': 'Neil D. Palmisiano', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Monmouth Medical Center', 'geoPoint': {'lat': 40.30428, 'lon': -73.99236}}, {'zip': '07748', 'city': 'Middletown', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '212-639-7592'}, {'name': 'Xin Wang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Memorial Sloan Kettering Monmouth', 'geoPoint': {'lat': 40.39428, 'lon': -74.11709}}, {'zip': '07645', 'city': 'Montvale', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '212-639-7592'}, {'name': 'Xin Wang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Memorial Sloan Kettering Bergen', 'geoPoint': {'lat': 41.04676, 'lon': -74.02292}}, {'zip': '08903', 'city': 'New Brunswick', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '732-235-7356'}, {'name': 'Neil D. Palmisiano', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Rutgers Cancer Institute of New Jersey', 'geoPoint': {'lat': 40.48622, 'lon': -74.45182}}, {'zip': '07652', 'city': 'Paramus', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'clinicaltrialsresearch@valleyhealth.com', 'phone': '201-634-5792'}, {'name': 'Jason Suh', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'The Valley Hospital - Luckow Pavilion', 'geoPoint': {'lat': 40.94454, 'lon': -74.07542}}, {'zip': '07450', 'city': 'Ridgewood', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'clinicaltrialsresearch@valleyhealth.com', 'phone': '201-634-5792'}, {'name': 'Jason Suh', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Valley Health System Ridgewood Campus', 'geoPoint': {'lat': 40.97926, 'lon': -74.11653}}, {'zip': '08755', 'city': 'Toms River', 'state': 'New Jersey', 'status': 'SUSPENDED', 'country': 'United States', 'facility': 'Community Medical Center', 'geoPoint': {'lat': 39.95373, 'lon': -74.19792}}, {'zip': '87106', 'city': 'Albuquerque', 'state': 'New Mexico', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'HSC-ClinicalTrialInfo@salud.unm.edu', 'phone': '505-925-0348'}, {'name': 'Charles Foucar', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of New Mexico Cancer Center', 'geoPoint': {'lat': 35.08449, 'lon': -106.65114}}, {'zip': '14263', 'city': 'Buffalo', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'askroswell@roswellpark.org', 'phone': '800-767-9355'}, {'name': 'Eunice S. Wang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Roswell Park Cancer Institute', 'geoPoint': {'lat': 42.88645, 'lon': -78.87837}}, {'zip': '11725', 'city': 'Commack', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '212-639-7592'}, {'name': 'Xin Wang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Memorial Sloan Kettering Commack', 'geoPoint': {'lat': 40.84288, 'lon': -73.29289}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '212-639-7592'}, {'name': 'Xin Wang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Memorial Sloan Kettering Cancer Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '14642', 'city': 'Rochester', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '585-275-5830'}, {'name': 'Paul M. Barr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Rochester', 'geoPoint': {'lat': 43.15478, 'lon': -77.61556}}, {'zip': '10467', 'city': 'The Bronx', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'eskwak@montefiore.org', 'phone': '718-379-6866'}, {'name': 'Ioannis Mantzaris', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Montefiore Medical Center - Moses Campus', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '11553', 'city': 'Uniondale', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '212-639-7592'}, {'name': 'Xin Wang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Memorial Sloan Kettering Nassau', 'geoPoint': {'lat': 40.70038, 'lon': -73.59291}}, {'zip': '28203', 'city': 'Charlotte', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '800-804-9376'}, {'name': 'Thomas G. Knight', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Carolinas Medical Center/Levine Cancer Institute', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '28204', 'city': 'Charlotte', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'kashah@novanthealth.org', 'phone': '980-201-6360'}, {'name': 'Patricia L. Kropf', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Novant Health Presbyterian Medical Center', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '27710', 'city': 'Durham', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '888-275-3853'}, {'name': 'Harry P. Erba', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Duke University Medical Center', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'zip': '27103', 'city': 'Winston-Salem', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'pjordan@novanthealth.org', 'phone': '336-718-8335'}, {'name': 'James P. Dugan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Novant Health Forsyth Medical Center', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'zip': '27157', 'city': 'Winston-Salem', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '336-713-6771'}, {'name': 'Bayard L. Powell', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Wake Forest University Health Sciences', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'zip': '44106', 'city': 'Cleveland', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CTUReferral@UHhospitals.org', 'phone': '800-641-2422'}, {'name': 'Ali W. Bseiso', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Case Western Reserve University', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '73104', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'ou-clinical-trials@ouhsc.edu', 'phone': '405-271-8777'}, {'name': 'Manu Pandey', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Oklahoma Health Sciences Center', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '97914', 'city': 'Ontario', 'state': 'Oregon', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'mccinfo@mtcancer.org', 'phone': '406-969-6060'}, {'name': 'Tareq Al baghdadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Saint Alphonsus Cancer Care Center-Ontario', 'geoPoint': {'lat': 44.02655, 'lon': -116.96294}}, {'zip': '97213', 'city': 'Portland', 'state': 'Oregon', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CanRsrchStudies@providence.org', 'phone': '503-215-2614'}, {'name': 'Charles W. Drescher', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Providence Portland Medical Center', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '97225', 'city': 'Portland', 'state': 'Oregon', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CanRsrchStudies@providence.org', 'phone': '503-215-2614'}, {'name': 'Charles W. Drescher', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Providence Saint Vincent Medical Center', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '18103', 'city': 'Allentown', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Morgan_M.Horton@lvhn.org', 'phone': '610-402-9543'}, {'name': 'Tareq Al baghdadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Lehigh Valley Hospital-Cedar Crest', 'geoPoint': {'lat': 40.60843, 'lon': -75.49018}}, {'zip': '17822', 'city': 'Danville', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'HemonCCTrials@geisinger.edu', 'phone': '570-271-5251'}, {'name': 'Joseph J. Vadakara', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Geisinger Medical Center', 'geoPoint': {'lat': 40.96342, 'lon': -76.61273}}, {'zip': '17033-0850', 'city': 'Hershey', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CTO@hmc.psu.edu', 'phone': '717-531-3779'}, {'name': 'Joseph Cioccio', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Penn State Milton S Hershey Medical Center', 'geoPoint': {'lat': 40.28592, 'lon': -76.65025}}, {'zip': '17044', 'city': 'Lewistown', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'HemonCCTrials@geisinger.edu', 'phone': '717-242-7703'}, {'name': 'Joseph J. Vadakara', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Lewistown Hospital', 'geoPoint': {'lat': 40.59924, 'lon': -77.57138}}, {'zip': '15232', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '412-647-8073'}, {'name': 'Annie P. Im', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Pittsburgh Cancer Institute (UPCI)', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '19611', 'city': 'West Reading', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '610-988-9323'}, {'name': 'Terrence P. Cescon', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Reading Hospital', 'geoPoint': {'lat': 40.3337, 'lon': -75.94743}}, {'zip': '29316', 'city': 'Boiling Springs', 'state': 'South Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Kim.Williams3@prismahealth.org', 'phone': '864-522-4317'}, {'name': 'Suzanne R. Fanning', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Prisma Health Cancer Institute - Spartanburg', 'geoPoint': {'lat': 35.04651, 'lon': -81.98177}}, {'zip': '29640', 'city': 'Easley', 'state': 'South Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Kim.Williams3@prismahealth.org', 'phone': '864-522-4317'}, {'name': 'Suzanne R. Fanning', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Prisma Health Cancer Institute - Easley', 'geoPoint': {'lat': 34.82984, 'lon': -82.60152}}, {'zip': '29605', 'city': 'Greenville', 'state': 'South Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Kim.Williams3@prismahealth.org', 'phone': '864-522-4317'}, {'name': 'Suzanne R. Fanning', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Prisma Health Cancer Institute - Butternut', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '29605', 'city': 'Greenville', 'state': 'South Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Kim.Williams3@prismahealth.org', 'phone': '864-522-4317'}, {'name': 'Suzanne R. Fanning', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Prisma Health Cancer Institute - Faris', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '29615', 'city': 'Greenville', 'state': 'South Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Kim.Williams3@prismahealth.org', 'phone': '864-522-4317'}, {'name': 'Suzanne R. Fanning', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Prisma Health Cancer Institute - Eastside', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '29650', 'city': 'Greer', 'state': 'South Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Kim.Williams3@prismahealth.org', 'phone': '864-522-4317'}, {'name': 'Suzanne R. Fanning', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Prisma Health Cancer Institute - Greer', 'geoPoint': {'lat': 34.93873, 'lon': -82.22706}}, {'zip': '29672', 'city': 'Seneca', 'state': 'South Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Kim.Williams3@prismahealth.org', 'phone': '864-522-4317'}, {'name': 'Suzanne R. Fanning', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Prisma Health Cancer Institute - Seneca', 'geoPoint': {'lat': 34.68566, 'lon': -82.9532}}, {'zip': '38017', 'city': 'Collierville', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'BCCclintrials@bmhcc.org', 'phone': '901-226-1366'}, {'name': 'Salil Goorha', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Baptist Memorial Hospital and Cancer Center-Collierville', 'geoPoint': {'lat': 35.04204, 'lon': -89.66453}}, {'zip': '38120', 'city': 'Memphis', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'BCCclintrials@bmhcc.org', 'phone': '901-226-1366'}, {'name': 'Salil Goorha', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Baptist Memorial Hospital and Cancer Center-Memphis', 'geoPoint': {'lat': 35.14953, 'lon': -90.04898}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'burton@bcm.edu', 'phone': '713-798-1354'}, {'name': 'Tareq Abuasab', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '713-873-2000'}, {'name': 'Tareq Abuasab', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Ben Taub General Hospital', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '84112', 'city': 'Salt Lake City', 'state': 'Utah', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'cancerinfo@hci.utah.edu', 'phone': '888-424-2100'}, {'name': 'Paul J. Shami', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Huntsman Cancer Institute/University of Utah', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '22908', 'city': 'Charlottesville', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'uvacancertrials@hscmail.mcc.virginia.edu', 'phone': '434-243-6303'}, {'name': 'Daniel R. Reed', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Virginia Cancer Center', 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}, {'zip': '22031', 'city': 'Fairfax', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Stephanie.VanBebber@inova.org', 'phone': '703-720-5210'}, {'name': 'Danielle A. Shafer', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Inova Schar Cancer Institute', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}, {'zip': '22042', 'city': 'Falls Church', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'Stephanie.VanBebber@inova.org', 'phone': '703-208-6650'}, {'name': 'Danielle A. Shafer', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Inova Fairfax Hospital', 'geoPoint': {'lat': 38.88233, 'lon': -77.17109}}, {'zip': '98026', 'city': 'Edmonds', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'PCRC-NCORP@Swedish.org', 'phone': '206-215-2343'}, {'name': 'Charles W. Drescher', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Swedish Cancer Institute-Edmonds', 'geoPoint': {'lat': 47.81065, 'lon': -122.37736}}, {'zip': '98029', 'city': 'Issaquah', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'PCRC-NCORP@Swedish.org', 'phone': '206-215-2343'}, {'name': 'Charles W. Drescher', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Swedish Cancer Institute-Issaquah', 'geoPoint': {'lat': 47.5301, 'lon': -122.03262}}, {'zip': '98122', 'city': 'Seattle', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'PCRC-NCORP@Swedish.org', 'phone': '206-215-2343'}, {'name': 'Charles W. Drescher', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Swedish Medical Center-First Hill', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '54806', 'city': 'Ashland', 'state': 'Wisconsin', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'CancerTrials@EssentiaHealth.org', 'phone': '218-786-3308'}, {'name': 'Bret E. Friday', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Duluth Clinic Ashland', 'geoPoint': {'lat': 46.59244, 'lon': -90.8838}}, {'zip': '54301', 'city': 'Green Bay', 'state': 'Wisconsin', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'WI_research_admin@hshs.org', 'phone': '920-433-8889'}, {'name': 'Matthew L. Ryan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Saint Vincent Hospital Cancer Center Green Bay', 'geoPoint': {'lat': 44.51916, 'lon': -88.01983}}, {'zip': '54303', 'city': 'Green Bay', 'state': 'Wisconsin', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'wi_research_admin@hshs.org', 'phone': '920-433-8889'}, {'name': 'Matthew L. Ryan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Saint Vincent Hospital Cancer Center at Saint Mary's", 'geoPoint': {'lat': 44.51916, 'lon': -88.01983}}, {'zip': '54601', 'city': 'La Crosse', 'state': 'Wisconsin', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'cancerctr@gundersenhealth.org', 'phone': '608-775-2385'}, {'name': 'Kurt Oettel', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Gundersen Lutheran Medical Center', 'geoPoint': {'lat': 43.80136, 'lon': -91.23958}}, {'zip': '53226', 'city': 'Milwaukee', 'state': 'Wisconsin', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '414-805-3666'}, {'name': 'Karen-Sue B. Carlson', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Medical College of Wisconsin', 'geoPoint': {'lat': 43.0389, 'lon': -87.90647}}, {'zip': '54482', 'city': 'Stevens Point', 'state': 'Wisconsin', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'oncology.clinical.trials@marshfieldresearch.org', 'phone': '800-782-8581'}, {'name': 'Adedayo A. Onitilo', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Marshfield Medical Center-River Region at Stevens Point', 'geoPoint': {'lat': 44.52358, 'lon': -89.57456}}, {'zip': '54476', 'city': 'Weston', 'state': 'Wisconsin', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'oncology.clinical.trials@marshfieldresearch.org', 'phone': '800-782-8581'}, {'name': 'Adedayo A. Onitilo', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Marshfield Medical Center - Weston', 'geoPoint': {'lat': 44.8908, 'lon': -89.54762}}, {'zip': 'T2N 5G2', 'city': 'Calgary', 'state': 'Alberta', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'ctsucontact@westat.com', 'phone': '888-823-5923'}, {'name': 'Mary L. Savoie', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Arthur J E Child Comprehensive Cancer Centre', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'zip': 'T6G 2B7', 'city': 'Edmonton', 'state': 'Alberta', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'pedsoncologyresearch@ahs.ca', 'phone': '780-407-8798'}, {'name': 'Joseph M. Brandwein', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Alberta Hospital', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'zip': 'R3E 0V9', 'city': 'Winnipeg', 'state': 'Manitoba', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'ctu_web@cancercare.mb.ca', 'phone': '866-561-1026'}, {'name': 'Brett L. Houston', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CancerCare Manitoba', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}}, {'zip': 'B3H 2Y9', 'city': 'Halifax', 'state': 'Nova Scotia', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '902-473-6000'}, {'name': 'Mahmoud Elsawy', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'QEII Health Sciences Centre/Nova Scotia Health Authority', 'geoPoint': {'lat': 44.64269, 'lon': -63.57688}}, {'zip': 'L8V 5C2', 'city': 'Hamilton', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '905-387-9495'}, {'name': 'Alejandro Garcia-Horton', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Juravinski Cancer Centre at Hamilton Health Sciences', 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'zip': 'J4V 2H1', 'city': 'Greenfield Park', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '450-466-5065'}, {'name': 'Sami Morin-Ben Abdallah', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CSSS Champlain-Charles Le Moyne', 'geoPoint': {'lat': 45.48649, 'lon': -73.46223}}, {'zip': 'H1T 2M4', 'city': 'Montreal', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '514-252-3400', 'phoneExt': '3329'}, {'name': 'Julie Bergeron', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CIUSSSEMTL-Hopital Maisonneuve-Rosemont', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'H3T 1E2', 'city': 'Montreal', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '514-340-8222', 'phoneExt': '8248'}, {'name': 'Sarit E. Assouline', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Jewish General Hospital', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': '00927', 'city': 'San Juan', 'status': 'RECRUITING', 'country': 'Puerto Rico', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'email': 'ctsucontact@westat.com', 'phone': '888-823-5923'}, {'name': 'Luis J. Santos Reyes', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centro Comprensivo de Cancer de UPR', 'geoPoint': {'lat': 18.46633, 'lon': -66.10572}}, {'zip': '00936', 'city': 'San Juan', 'status': 'RECRUITING', 'country': 'Puerto Rico', 'contacts': [{'name': 'Site Public Contact', 'role': 'CONTACT', 'phone': '787-763-1296'}, {'name': 'Luis J. Santos Reyes', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'San Juan City Hospital', 'geoPoint': {'lat': 18.46633, 'lon': -66.10572}}], 'overallOfficials': [{'name': 'Mary L Savoie', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Canadian Cancer Trials Group'}]}, 'ipdSharingStatementModule': {'url': 'https://grants.nih.gov/policy/sharing.htm', 'ipdSharing': 'YES', 'description': 'NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}, 'responsibleParty': {'type': 'SPONSOR'}}}}